Loading...
NPI 1245343532 · Great Neck, NY · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jeffrey Shakin is a ophthalmology physician provider located in Great Neck, New York. This profile covers 24 Medicare and 9 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Jeffrey Shakin |
| Address | 600 Northern Blvd |
| City | Great Neck |
| State | NY |
| ZIP | 11021 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | August 17, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.4M |
| Medicaid | $82.4K |
Provider JEFFREY SHAKIN has an established NPI enumerated on 2006-08-17 (~20 years ago) and shows a strongly Medicare-weighted revenue profile: Total Medicare revenue is $4.4M while Total Medicaid revenue is $82.4K, indicating the practice is effectively Medicare-dominated in scale. This tenure and payer mix suggest a seasoned outpatient practice primarily serving the Medicare population rather than Medicaid.
Medicare revenue is highly concentrated: the precomputed top three Medicare codes account for 77.6% of the provider's total Medicare revenue, driven primarily by J0178 ($2.6M, 58.0%), Q5128 ($597.2K, 13.5%), and 67028 ($275K, 6.2%). These three codes are all intravitreal drug administrations or the injection procedure itself, signaling an operation centered on anti-VEGF intravitreal injections as the core service line.
Clinical and operational mix reinforces a retina/injection clinic model: high revenue from J0178 (aflibercept) and Q5128 (ranibizumab biosimilar) together with procedural billing for 67028 indicates repeated, procedural drug administration visits rather than a surgery-heavy ophthalmology practice. The presence of 92134 ($153K, 3.5%)—computerized retinal imaging—further supports a workflow that pairs diagnostic imaging with frequent injection visits.
The provider is a high-volume national participant for several injection- and imaging-related codes: J0178 ranks #91 of 3204 nationally (97th percentile; notably above typical national volume for this code), 67028 ranks #209 of 4255 (95th percentile; notably above typical national volume for this code), and 92134 ranks #116 of 26868 (100th percentile; extreme outlier). These placements indicate above-typical to extreme outlier utilization nationally for core retina injections and imaging, consistent with a focused high-throughput injection clinic.
Medicaid activity is minimal in absolute terms but similarly concentrated: the precomputed top three Medicaid codes account for 79.8% of the provider's Medicaid revenue, led by J2778 ($26.1K, 31.9%), 67028 ($25.7K, 31.4%), and J0178 ($13.6K, 16.6%). Despite that concentration, the overall Medicaid total of $82.4K and in-state ranks (for example, J0178 at #93 of 101, 7th percentile) show the provider is a modest participant in the state Medicaid market compared with its national Medicare presence.
Visit-volume signals support the high-throughput model: 99213 generated $113.1K (2.6% of Medicare revenue) across 1.4K claims and ranks #2493 of 457151 nationally (99th percentile; extreme outlier), indicating frequent brief established-patient visits consistent with injection follow-ups and monitoring visits rather than primarily longer new-patient consultations. High counts of lower-complexity E/M and imaging codes align with recurring short visits typical of intravitreal injection clinics.
There is evidence of substantial high-cost drug billing activity beyond the named anti-VEGF codes: J3490 (Unclassified drugs) contributed $122.4K (2.8% of Medicare revenue), which may reflect occasional billing for miscellaneous or high-cost injectable drugs not captured under a specific HCPCS. This pattern, together with the large share from J0178, underscores that drug administration is the primary revenue driver and that drug mix and reimbursement changes could materially affect revenue.
Because 77.6% of Medicare revenue and 79.8% of Medicaid revenue are concentrated in the top three codes for each payer, the practice has operational sensitivity to utilization and reimbursement shifts in a small set of injection and imaging codes. Combined with the Medicare-dominant payer mix ($4.4M vs $82.4K), payer-contracting and reimbursement policy changes for intravitreal agents should be a focus for payers or competitor analysts evaluating the business continuity and competitive positioning of this provider.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
24 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 3,730 | $690 | $2.6M |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 2,770 | $220 | $597.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,410 | $110 | $275K |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 900 | $180 | $156.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 4,130 | $40 | $153K |
| J3490 | Unclassified drugs | 60 | $1,910 | $122.4K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,430 | $80 | $113.1K |
| J2778 | Injection, ranibizumab, 0.1 mg | 630 | $180 | $110.6K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 2,880 | $30 | $83.5K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 1,010 | $80 | $81.9K |
Showing 1–10 of 24
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 24 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
24 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 8 | 230 | 560 | $690 | $693K |
| J2777 | 100 | 120 | 7,740 | $30 | $364.9K |
| Q5128 | 2 | 20 | 1,170 | $220 | $268.3K |
| J2778 | 31 | 70 | 510 | $180 | $131.6K |
| J2781 | 30 | 40 | 520 | $120 | $75.1K |
| Q5124 | 2 | 20 | 310 | $170 | $69.7K |
| 67028 | 7 | 300 | 400 | $100 | $65.9K |
| J3490 | 54 | 120 | 60 | $470 | $50.8K |
| 92014 | 974 | 2,220 | 160 | $100 | $29.3K |
| 99214 | 27,261 | 30,450 | 90 | $100 | $19K |
Showing 1–10 of 24
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2778 | Injection, ranibizumab, 0.1 mg | 70 | $350 | $26.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 590 | $40 | $25.7K |
| J0178 | Injection, aflibercept, 1 mg | 30 | $540 | $13.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,390 | $10 | $11.1K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 190 | $20 | $3.2K |
| 92226 | N/A | 270 | $10 | $1.9K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 40 | $10 | $190 |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 10 | $10 | $140 |
| 4177F | No Summary found for this code | 20 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
9 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 93 | 100 | 280 | $650 | $369.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 17,954 | 19,110 | 360 | $70 | $321K |
| J2778 | Injection, ranibizumab, 0.1 mg | 7 | 10 | 110 | $500 | $160.1K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 840 | 1,460 | 310 | $60 | $88.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 115 | 260 | 420 | $70 | $65.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 189 | 730 | 370 | $20 | $30K |
| 92226 | N/A | 205 | 400 | 270 | $20 | $12.6K |
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 245 | 320 | 190 | $20 | $10.7K |
| 4177F | No Summary found for this code | 14 | 20 | 80 | $1 | $10 |
Other providers in the same ZIP code as Jeffrey Shakin, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| C And T Homecare Services LLC | NY | In Home Supportive Care Agency | $0 | $847.7M |
| North Shore-lij Medical PC | NY | Urology Physician | $0 | $388.1M |
| First Choice Home Care Inc | NY | Home Health Agency | $0 | $28M |
| Welllife Network Inc. | NY | Clinic/Center | $0 | $22M |
| Regioncare Inc. | NY | Home Infusion Agency | $40.1K | $9.4M |
| Philip Ferrone | NY | Ophthalmology Physician | $3.1M | $10.5K |
| Shahram Shamekh | NY | Internal Medicine Physician | $673.3K | $1.4M |
| Angela Azar | NY | Dermatology Physician | $104.5K | $1.5M |
| Alireza Shirvani | NY | Hospitalist Physician | $1.4M | $178K |
| Stephanie Buck-haskin | NY | Obstetrics & Gynecology Physician | $56.1K | $1.4M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.